يبحث (أخبار)

HUTCHMED Highlights Pivotal Phase II Data For Fanregratinib In Intrahepatic Cholangiocarcinoma Presented At ESMO Gastrointestinal Cancers Congress 2026

english top health

(MENAFN - GlobeNewsWire - Nasdaq) - Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control - - Fanregratinib holds ...
2026-06-24 20:01:18